Best Researcher Award
David Hong
MD Anderson Cancer Center, United States
David S. Hong is a professor in Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. His documented research profile encompasses oncology, early-phase clinical trials, molecularly informed cancer treatment, and translational investigation. His ORCID record identifies the same Scopus Author ID supplied for this profile and lists phase I clinical trials, oncology, and cancer among his research keywords. [1] His published work also includes studies involving clinical next-generation sequencing and genomic characterization intended to support precision oncology. [2]
Abstract
David S. Hong is a physician-scientist and professor at The University of Texas MD Anderson Cancer Center whose research integrates investigational therapeutics, molecular oncology, precision medicine, and cancer genomics. His scholarly record includes clinical studies examining genomic alterations, targeted therapies, immunotherapy, and early-phase therapeutic development. His ORCID profile associates him with phase I clinical trials, oncology, and cancer, while published studies demonstrate participation in genomic profiling and molecular characterization of tumors. [1] [2] These activities provide a substantive basis for consideration within a research recognition framework focused on computationally informed cancer biology.
Keywords
Cancer genomics, computational oncology, precision medicine, molecular oncology, next-generation sequencing, investigational therapeutics, phase I clinical trials, targeted therapy, translational research, genomic profiling.
Introduction
Computational approaches increasingly connect genomic measurements with clinical decision-making in precision oncology. Within this research environment, David S. Hong has contributed to investigations in which molecular profiling, cancer biology, and therapeutic development intersect. His institutional profile identifies him as a professor in Investigational Cancer Therapeutics at MD Anderson Cancer Center. [3] His publication record includes research addressing actionable genomic alterations and molecular characterization of advanced cancers, supporting the relevance of his work to data-driven cancer research. [2]
Research Profile
Hong’s research profile is centered on investigational cancer therapeutics and the molecular basis of cancer, with particular relevance to early-phase clinical development. His ORCID record identifies phase I clinical trials, oncology, and cancer as keywords, while institutional information places his work within Investigational Cancer Therapeutics. [1] [3] This combination creates a translational research pathway in which molecular evidence can inform therapeutic hypotheses, clinical trial design, and assessment of emerging treatment strategies.
Research Contributions
A significant component of Hong’s documented research involves the use of molecular and genomic information in oncology. A study of clinical next-generation sequencing in a phase I program examined recurrent hotspot mutations across cancer-related genes and was associated with Bioinformatics & Computational Biology and Systems Biology research areas at MD Anderson. [2] Other work has addressed comprehensive molecular characterization of KRAS G12C-mutant colorectal cancer, demonstrating the relevance of genomic alterations to precision oncology research. [4]
Publications
Hong has participated in peer-reviewed research covering clinical next-generation sequencing, genomic profiling, molecularly defined cancers, targeted treatment, and investigational therapeutics. His ORCID record currently lists hundreds of works in its broader publication record, including recent articles and contributions indexed through Crossref. [1] A representative genomic study, “Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers,” reported the application of sequencing approaches to precision oncology and included Hong among its authors. [5]
Research Impact
The supplied bibliometric profile reports 560 documents, 39,661 citations, and an h-index of 100. These figures are presented here as supplied profile data rather than independently recalculated metrics. The underlying research record demonstrates engagement with genomic characterization, molecular profiling, and therapeutic development, areas that contribute to the broader evidence base for precision cancer medicine. [2] [5] Recent institutional and ORCID records also confirm an ongoing research role at MD Anderson. [1] [3]
Award Suitability
For the Best Researcher Award associated with the Computational Biologists Awards, Hong’s profile is relevant through its intersection of cancer genomics, computationally supported molecular research, precision oncology, and translational therapeutics. His documented participation in studies using next-generation sequencing and genomic characterization provides direct subject-area relevance, while his institutional position and publication record indicate sustained engagement with cancer research. [2] [3] Final award decisions should remain subject to the organizer’s formal evaluation criteria and independent verification of submitted bibliometric information.
Conclusion
David S. Hong’s documented research connects investigational cancer therapeutics with molecular oncology and genomic approaches to precision medicine. Evidence from institutional, ORCID, and scholarly sources supports his involvement in clinical and translational cancer research, including genomic profiling and molecular characterization. [1] [3] On the basis of the supplied profile information, his research trajectory presents a credible alignment with a recognition category emphasizing sustained scholarly contribution and computationally informed cancer research.
External Links
References
- Elsevier. (n.d.). Scopus author details: David Hong, Author ID 34770051000. Scopus.
https://orcid.org/0000-0001-8721-1609
- cancer Resear. (2024). Abstract 1250: Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer.
https://doi.org/10.1158/1538-7445.AM2024-1250
- Clinical cancer Resear .(2010). A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors.
https://doi.org/10.1158/1078-0432.CCR-10-0631
- ORCID. (n.d.). ORCID record for David Hong.
https://orcid.org/0000-0001-8721-1609
- Computational Biologists Awards. (2026). Official Award Website.
https://computationalbiologists.com/